Citations

Clear

31 citation(s) found for "Lieu, Christopher".

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).
Guan, Yu, Puhalla, Shannon L. , Deming, Dustin A. , Philip, Philip Agop, Hong, Theodore S. , Rojas-Khalil, Yesenia, Lieu, Christopher H. , Kopetz, Scott , Lucas, Peter C. , Şahin, İbrahim Halil , Loree, Jonathan M. , Wolmark, Norman , Yothers, Greg , George, Thomas J. , Dasari, Arvind

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: No page available

10.1200/jco.2025.43.4_suppl.tps310 Get It

TPS310 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. CC pts who do not have detectable ctDNA (ctDNA-) are at a much lower risk of recurrence and may be spared the toxicities associated with AC. Furthermore, for CC pts with detectable ctDNA (ctDNA+) who are at a very high risk of recurrence, the optimal AC regimen has not been established. We hypothesize that for pts whose CC has been resected, ctDNA status may be used to risk-stratify for making decisions about AC. Methods: In this prospective phase II/III trial, up to 1,912 pts with resected stage IIB, IIC, and III CC will be enrolled. Based on the post-operative ctDNA status using personalized and tumor-informed assay (Signatera, bespoke assay), those who are ctDNA- (Cohort A) will be randomized to immediate AC with fluoropyrimidine (FP)+oxaliplatin (Ox) for 3-6 mos per established guidelines v serial ctDNA monitoring. Patients who are ctDNA+ post-operatively, or with serial monitoring (Cohort B), will be randomized to FP+Ox v more intensive AC with addition of irinotecan (I) for 6 mos. One cycle of chemotherapy is allowed while awaiting ctDNA testing results for cohort assignment. The primary endpoints for Cohort A are time to ctDNA+ status (phase II) and disease-free survival (DFS) (phase III) in the immediate v delayed AC arms. The primary endpoint for Cohort B is DFS in the FP+Ox v FP+Ox+I arms for both phase II and phase III portions of the trial. Secondary endpoints include prevalence of detectable ctDNA post-operatively, time-to-event outcomes (overall survival and time to recurrence) by ctDNA status, and the assessment of compliance to adjuvant therapy. Biospecimens including archival tumor tissue, as well as post-operative plus serial matched/normal blood samples, will be collected for exploratory correlative research. Active enrollment across the NCTN started in June 2022 with CCTG sites joining in August 2023. Current accrual (as of 9-20-2024): 500/1,912. Clinical trial information: NCT05174169 .
623 Final results from phase 1, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Geva, Ravit , Golan, Talia , Cohen, Jonathan , Zhaohui, Jin, LoRusso, Patricia , Friedman, Itay, Hakim, Motti, Ziv, Dana Haves, Hashmueli, Sharon, Mandel, Ilana , Moshe, Tehila Ben, Crawford, Nigel P.S., Abbadessa, Giovanni , Wu, Meijing, Perets, Ruth , Stemmer, Salomon M. , Fakih, Marwan , Lieu, Christopher H. , Zhaohui, Jin, Crawford, Nigel, Perez, Raymond P. , Borad, Mitesh J.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A717-A717

10.1136/jitc-2024-sitc2024.0623 Get It

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
Guan, Yu, Puhalla, Shannon L. , Sahin, Ibrahim Halil, Deming, Dustin A. , Hong, Theodore S. , Rojas-Khalil, Yesenia, Dasari, Arvind , Kopetz, Scott , Lucas, Peter C. , Şahin, İbrahim Halil , Philip, Philip A. , Loree, Jonathan M. , Wolmark, Norman , Yothers, Greg , George, Thomas J. , Lieu, Christopher H.

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3641-TPS3641

10.1200/jco.2024.42.16_suppl.tps3641 Get It

TPS3641 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. CC pts who do not have detectable ctDNA (ctDNA-) are at a much lower risk of recurrence and may be spared the toxicities associated with AC. Furthermore, for CC pts with detectable ctDNA (ctDNA+) who are at a very high risk of recurrence, the optimal AC regimen has not been established. We hypothesize that for pts whose CC has been resected, ctDNA status may be used to risk-stratify for making decisions about AC. Methods: In this prospective phase II/III trial, up to 1,912 pts with resected stage IIB, IIC, and III CC will be enrolled. Based on the post-operative ctDNA status using personalized and tumor-informed assay (Signatera, bespoke assay), those who are ctDNA- (Cohort A) will be randomized to immediate AC with fluoropyrimidine (FP)+oxaliplatin (Ox) for 3-6 mos per established guidelines vserial ctDNA monitoring. Patients who are ctDNA+ post-operatively, or with serial monitoring (Cohort B), will be randomized to FP+Ox v more intensive AC with addition of irinotecan (I) for 6 mos. One cycle of chemotherapy is allowed while awaiting ctDNA testing results for cohort assignment. The primary endpoints for Cohort A are time to ctDNA+ status (phase II) and disease-free survival (DFS) (phase III) in the immediate v delayed AC arms. The primary endpoint for Cohort B is DFS in the FP+Ox v FP+Ox+I arms for both phase II and phase III portions of the trial. Secondary endpoints include prevalence of detectable ctDNA post-operatively, time-to-event outcomes (overall survival and time to recurrence) by ctDNA status, and the assessment of compliance to adjuvant therapy. Biospecimens including archival tumor tissue, as well as post-operative plus serial matched/normal blood samples, will be collected for exploratory correlative research. Active enrollment across the NCTN started in June 2022 with CCTG sites joining in August 2023. Current accrual (as of 02-02-2024) is 240/1,912. NCT05174169. Support: U10-CA-180868, -180822; UG1CA-189867; Natera, Inc. Clinical trial information: NCT05174169 .
Genomic landscapes of early-onset versus average-onset colorectal cancer populations.
Stoppler, Melissa C. , Storandt, Michael H. , Shi, Qian , Eng, Cathy , Lieu, Christopher H. , George, Thomas J. , Mauer, Elizabeth , Teslow, Emily A. , Mahipal, Amit , Jin, Zhaohui

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 3536-3536

10.1200/jco.2023.41.16_suppl.3536 Get It

3536 Background: Early-onset colorectal cancer (eoCRC, initial CRC diagnosis at age < 50 years) has been increasing in the past two decades especially in Western countries. This study evaluates somatic and germline profiles in eoCRC compared to average-onset CRC (aoCRC, initial CRC diagnosis at age ≥ 50 years). Methods: This is a retrospective, cross-sectional study utilizing data from de-identified records of colorectal cancer patients tested with the Tempus xT assay from 2017 to 2022. Briefly, the assay is a targeted panel that detects single nucleotide variants, insertions and/or deletions, and copy number variants in 598-648 genes, as well as chromosomal rearrangements in 22 genes with high sensitivity and specificity. Baseline characteristics and immunologic markers were compared between eoCRC and aoCRC by Wilcoxon Rank Sum or Chi-squared test (reporting p-values). Somatic and germline mutations were compared between two age groups with false discover rate adjustments (reporting q-values). Results: In this study, 2,379 eoCRC and 8,627 aoCRC patients were included, with the majority diagnosed with stage IV disease. Additionally, germline alterations were assessed on a subset of 6,311 patients with tumor/normal match testing (eoCRC = 1,413 and aoCRC = 4,898). Left-sided primaries were more common in eoCRC (85% left/rectum in eoCRC vs. 75% left/rectum in aoCRC (p < 0.001), and rates of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) were lower compared to aoCRC (4.2% vs. 6.8%, p < 0.001). eoCRC has a unique somatic mutation profile compared to aoCRC. A higher prevalence of germline mutations was observed in eoCRC overall (6.9% vs. 5%, p = 0.006); however, no statistically significant differences were observed in individual germline genes compared to aoCRC, likely due to relatively small numbers. Conclusions: eoCRC has a unique mutational profile and presence of germline mutations in 6.9% of eoCRC, indicating a potential role for universal germline testing in CRC. [Table: see text]
Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.
Douillard, Jean‐Yves , Maughan, Tim , Lenz, Heinz‐Josef , Heinemann, Volker , Bokemeyer, Carsten , Gramont, Aimery de , Maughan, Timothy S , Jin, Zhaohui , Dixon, Jesse G. , Hubbard, Joleen M. , Eng, Cathy , Lieu, Christopher H. , Adams, Richard , Cutsem, Eric Van , Venook, Alan P. , Stintzing, Sebastian , Kaplan, Richard , Chibaudel, Benoist , Zalcberg, John , Yoshino, Takayuki , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 3572-3572

10.1200/jco.2022.40.16_suppl.3572 Get It

3572 Background: Early onset colorectal cancer (eoCRC: disease diagnosed < 50) has been increasing over the past 2 decades. Currently, standard treatment recommendations for eoCRC patients (pts) with metastatic disease does not differ from late-onset CRC (loCRC) pts although outcomes data in eoCRC pts is limited. Methods: Individual patient data on 5,761 treatment-naive metastatic eoCRC pts was pooled from 8 phase II and III randomized EGFRi studies (2000 - 2012) from the ARCAD mCRC database. The distribution of demographics, clinicopathological features, and biomarkers were summarized by age groups. Progression-free survival (PFS) was compared between age groups by stratified Cox models, adjusting for potential confounders. Predictive value of age group was evaluated by testing interaction effect between treatment and age variables based on a subset of trials with concurrent randomizations between regimens with and without EGFRi Results: eoCRC (n=756) were more evenly distributed between gender, had improved performance status (PS), increased likelihood of metastatic resection, and distant lymph node metastasis, but were less likely to have lung metastasis or KRAS mutation compared to loCRC (n=5,005, table 1). eoCRC and loCRC patients had similar distribution of primary tumor sidedness, primary resection, liver and/or peritoneal involvement, number of metastatic sites involved, and BRAF mutations (MT). No difference in PFS for eoCRC versus loCRC pts was noted (7.8 vs. 7.9 months [M], adjusted hazard ratio [HRadj], 1.02, 95% confidence interval [CI], 0.93-1.11). Among pts with KRAS wild type (WT) and left sided primary tumors, univariable analysis of EGFRi demonstrated improved mPFS in loCRC (9.9 vs 8.5M, HR = 0.74, p<0.001), but this benefit was not seen in eoCRC (8.3 vs 8.9 months, HR 1.20, p=0.36). The same pattern was observed upon multivariable analysis (Table). Conclusions: In our pooled analysis, EGFRi + chemotherapy significantly improved PFS in treatment-naïve loCRC patients but not in left sided, KRAS WT, eoCRC patients. Further validation in an independent cohort is warranted. [Table: see text]
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Chakravarty, Debyani , Johnson, Amber , Sklar, Jeffrey, Lindeman, Neal I., Moore, Kathleen N. , Ganesan, Shridar , Lovly, Christine M. , Perlmutter, Jane, Gray, Stacy W. , Hwang, Jimmy, Azad, Nilofer S. , Tafe, Laura, Tafe, Laura J. , Moore, Kathleen , Lieu, Christopher , André, Fabrice , Azad, Nilofer , Borad, Mitesh J , Messersmith, Hans , Robson, Mark , Meric-Bernstam, Funda , Gray, Stacy W , Chakravarty, Debyani , Johnson, Amber , Sklar, Jeffrey, Lindeman, Neal I., Ganesan, Shridar , Lovly, Christine Marie , Perlmutter, Jane, Hwang, Jimmy

Mayo Clinic

Journal of Clinical Oncology | February 17, 2022 | Volume: 40 | Issue: 11 | Pages: 1231-1258

10.1200/jco.21.02767 | PMID 35175857 Get It

PURPOSEAn ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors.CLINICAL CONTEXTAn increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. However, there is a lack of clarity as to when tumor genomic sequencing should be ordered, what type of assays should be performed, and how to interpret the results for treatment selection.PROVISIONAL CLINICAL OPINIONPatients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease. Multigene panel–based assays should be used if more than one biomarker-linked therapy is approved for the patient's disease. Site-agnostic approvals for any cancer with a high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase ( NTRK) fusions provide a rationale for genomic testing for all solid tumors. Multigene testing may also assist in treatment selection by identifying additional targets when there are few or no genotype-based therapy approvals for the patient's disease. For treatment planning, the clinician should consider the functional impact of the targeted alteration and expected efficacy of genomic biomarker–linked options relative to other approved or investigational treatments. Additional information is available at www.asco.org/assays-and-predictive-markers-guidelines .
Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.
Fiskum, Jack, Hurwitz, Herbert I. , Fuchs, Charles S. , Hecht, J. Randolph, Punt, Cornelis J.A. , Heinemann, Volker , Gramont, Aimery de , Jin, Zhaohui , Dixon, Jesse G. , Hubbard, Joleen M. , Eng, Cathy , Lieu, Christopher H. , Saltz, Leonard B. , Venook, Alan P. , Schmoll, Hans‐Joachim , Cremolini, Chiara , Díaz‐Rubio, Eduardo , Tebbutt, Niall C. , Yoshino, Takayuki , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 101-101

10.1200/jco.2022.40.4_suppl.101 Get It

101 Background: Colorectal cancer (CRC) incidence and mortality have decreased since the 1970s, but the incidence in young adults (20-49 years, named early-onset CRC, eoCRC) has been increasing. eoCRC patients with metastatic disease are treated with the same standard regimens as late-onset CRC (loCRC, age ≥ 50 years) although detailed response data for eoCRC are largely missing. Methods: Individual patient data on 7,604 subjects with metastatic eoCRC from 11 first line randomized bevacizumab studies between 2000 and 2012 in the ARCAD advanced colorectal cancer database were pooled. The distributions of demographics, clinicopathological features, biomarkers, and outcome data were summarized by age groups. Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for potential confounders. Predictive value of age group was evaluated by testing interaction effect between treatment and age variables. Results: Female eoCRC are more commonly seen compared to loCRC (46.8% vs. 38.7%, p<0.0001). Patients with eoCRC (n=1,289) were significantly more likely to have had prior metastasectomy (17.5% vs. 13.5%, p=0.043) and lung metastatic disease (67% vs. 59.8%, p<0.001), but less likely to have distant lymph node metastatic disease (58.8 vs. 62.9%, p=0.036) or KRAS mutation (29.2% vs. 34.4%, p=0.042) compared to those with loCRC (n=6,315). eoCRC and loCRC patients had similar distributions according to PS, primary tumor sidedness, prior primary tumor resection, liver involvement, peritoneal involvement, number of metastatic sites, NRAS and BRAF. Age of disease onset was not a statistically significant prognostic factor for PFS in univariate and multivariate analysis (seen in table). Bevacizumab in addition to chemo improved PFS in eoCRC population (9.9 vs. 6.8 months, HR = 0.66, p<0.001), which was similar to the findings in loCRC population (9.4 vs. 7.3 months, HR= 0.73, p<0.001, interaction p=0.54). By multivariate analysis, a greater improvement in PFS was noted for the addition of bevacizumab in eoCRC relative to LoCRC patients (HR = 0.62 vs. HR = 0.82). Conclusions: Treatment naive eoCRC patients with metastatic disease derive similar benefit from bevacizumab relative to their average age counterparts.[Table: see text]
Prognostic Impact of the Presence of Barrett’s Esophagus and Intestinal Metaplasia on Esophageal Adenocarcinoma Survival
Fox, Charlie, Friedman, Chloe , Marsh, Megan, McCarter, Martin D. , Kaplan, Jeffrey , Gleisner, Ana , Katzka, David A. , Wani, Sachin , Kolb, Jennifer M. , Scott, Frank I. , Han, Samuel , Lieu, Christopher H.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | August 20, 2021 | Volume: 2 | Issue: 4 | Pages: 356-364

10.1177/26345161211033277 | PMID 36578279 Get It

Background/Aims: Barrett’s esophagus (BE), defined by the presence of intestinal metaplasia (IM) on histology, is thought to be the only identifiable precursor lesion for esophageal adenocarcinoma (EAC). Recent studies have suggested the possibility of an alternate, non-IM associated EAC that is a more aggressive form of EAC with worse survival. Among EAC patients, we aimed to compare survival of patients with and without IM at the time of diagnosis. Methods: This was a retrospective cohort study of all patients with histologic confirmed EAC evaluated at a tertiary care center from 2013 to 2019. Cases were categorized according to the presence or absence of IM on histologic specimens (Group I—IM-EAC and Group II—non-IM-EAC). We compared demographic characteristics, clinical stage, therapy, and survival between the 2 groups using the Chi-square and ANOVA tests (for categorical and continuous variables, respectively). We used Cox proportional hazards regression to determine the association of IM with overall survival, adjusting for sex, age at diagnosis, tumor location, histologic grade, and clinical stage. Results: A total of 475 patients were included in this analysis (mean age 64.8 years [SD 10.8], 89% white) and 109 (23.0%) had no evidence of IM. Compared with IM-EAC (Group I), individuals in the non-IM-EAC group were younger ( P = .01) and had a greater proportion of patients diagnosed with advanced disease (49.5 vs 20.2% for stage 4, P < .001). These patients were less likely to undergo endoscopic therapy alone (0.92% vs 29.78%, P < .001) or surgery alone (0 vs 9.84%, P = .001). On multivariable analysis, the presence of IM-EAC was associated with improved overall survival compared to non-IM-EAC (HR 0.69, 95% CI 0.49-0.96). Additional factors associated with poor survival was increasing stage of diagnosis (HR 6.49: 95% CI 3.77-11.15 for stage 4, HR 2.19: 95% CI 1.25-3.84 for stage 3, HR 2.04: 95% CI 0.98-4.25 for stage 2 compared to stage 1) and more advanced histologic stage (HR 2.00, 95% CI 1.26-3.19) for poorly/undifferentiated compared to well differentiated). Conclusions: EAC without the presence of IM on histology was associated with worse survival compared to those with IM. Future prospective studies with detailed molecular sequencing are required to clarify if 2 separate phenotypes of EAC exist (IM-EAC and non-IM-EAC). If confirmed, this may have significant implications for screening and management strategies.
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, Manisha H. , Benson, Al B. , Bergsland, Emily K. , Blaszkowsky, Lawrence S. , Brock, Pamela , Chan, J.K.C., Das, Satya , Dickson, Paxton V. , Fanta, Paul T. , Giordano, Thomas J. , Halperin, Daniel M. , He, Jin , Heaney, Anthony P. , Heslin, Martin J. , Kandeel, Fouad , Kardan, Arash , Khan, Sajid , Kuvshinoff, Boris W. , Miller, Kimberly D. , Reidy‐Lagunes, Diane , Salgado, Sarimar Agosto , Shaheen, Shagufta , Sussman, Craig, Trikalinos, Nikolaos A. , Uboha, N., Vijayvergia, Namrata , Lynn, Beth, Hochstetler, Cindy, Trikalinos, Nikolaos A , Goldner, Whitney Sears , Hálfdánarson, Þorvarður R. , Lieu, Christopher H. , Pillarisetty, Venu Gopal , Soares, Heloisa P. , Soulen, Michael C , Strosberg, Jonathan , Wong, Terence Z.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 839-868

10.6004/jnccn.2021.0032 | PMID 34340212 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer
Collaborative, REACCT, Zaborowski, Alexandra , Abdile, Ahmed, Adamina, Michel , Aigner, Felix , d’Allens, Laura, Allmer, Caterina, Álvarez, Andrea, Anula, Rocío, Atallah, S. , Bach, Simon P. , Barussaud, Marie, Baušys, Augustinas , Bebington, Brendan , Beggs, Andrew D. , Bellolio, Felipe, Bennett, Melissa-Rose , Berdinskikh, Anton, Bevan, Vicki, Bislenghi, Gabriele , Bludau, Marc , Boutall, Adam , Brouwer, Nelleke P.M. , Bruns, Christiane J. , Burger, Jacobus W. A. , Бурлов, Никита , Campanelli, Michela , Capdepont, Maylis, Carvello, Michele , Chew, Hwee-Hoon, Christoforidis, Dimitri, Clark, David A. , Climent, Marta, Cologne, Kyle G. , Contreras, Tomás, Croner, Roland S. , Daniels, I. R. , Delrio, Paolo , Deutsch, Michael , D’Hoore, André , Drozdov, E. S. , Duek, Daniel, Dunlop, Malcolm G. , Edmundson, Aleksandra , Efetov, Sergey , El‐Hussuna, Alaa , Elliot, Brodie, Espín, Eloy , Faes, Seraina , Faiz, Omar , Frasson, Matteo , Figueiredo, Nuno , Forgan, Tim , Frizelle, Frank , Gadaev, Shamil, Gellona, José, Glyn, Tamara , Gong, Jianping, Barisic, Goran, Greenwood, Emma, Guren, Marianne G. , Guillon, Stephanie, Gutlic, Ida , Hanly, Ann, Hasegawa, Hirotoshi , Iversen, Lene Hjerrild , Hill, James , Hoch, Jiří, Hoffmeister, Michael , Hompes, Roel , Hurtado‐Pardo, Luis , Iaquinandi, Fabiano , Imbrasaitė, Ugnė , Jafari, Mehrenah Dorna, Kanemitsu, Yukihide , Karimuddin, Ahmer , Keller, Deborah S. , Kelly, Justin, Kennelly, Rory , Khrykov, Gleb , Kocián, Petr , Koh, Cherry , Kok, N. F. M., Knight, Katrina , Knol, Joep, Kontovounisios, Christos , Kørner, Hartwig , Kronberger, Irmgard, Kroon, Hidde M. , Kural, Said , Lakkis, Zaher , Lankov, Timur , Larson, Dave, Lázár, György , Lee, Kai-Yin , Lepistö, Anna , Loi, Lynette , Lynch, Craig, Maillou‐Martinaud, Helene, Maroli, Annalisa , Martling, Anna , Matzel, Klaus E. , Mayol, Julio , McDermott, Frank , Meurette, G. , Mitteregger, Martin , Моисеенко, А С, Monson, John R.T. , Moritani, Konosuke , Munini, Martino , Nahas, Caio Sérgio Rizkallah , Negoi, Ionuţ , Novikova, A , Ocares, Misael, Olkina, Alexandra, Oñate‐Ocaña, Luis F. , Otero, Jaime, Özen, Cihan , Pace, Ugo , Julião, Guilherme Pagin São , Panaiotti, Lidiia , Panís, Yves , Papamichael, Demetris , Uriburu, Juan C Patrón , Pera, Miguél , Perez, Rodrigo Oliva , Pfeffer, F. , Phang, P. Terry , Poškus, Tomas , Pringle, Heather , Proud, David , Raguz, Ivana , Rama, N. , Rasheed, Shahnawaz, Raval, Manoj J. , Reißfelder, Christoph , Meneses, Juan Carlos Reyes , Ris, Frédéric , Riss, Stefan , Rodríguez‐Zentner, Homero , Saklani, Avanish , Salido, Andrea Jiménez, Sammour, Tarik , Saraste, Deborah , Schneider, Martin , Seishima, Ryo , Sekulic, Aleksander , Seppälä, Toni T. , Sheahan, Kieran , Shine, Rebecca , Shlomina, Alexandra , Sica, Guiseppe S., Singnomklao, T, Siragusa, Leandro , Spinelli, Antonino , Staiger, Roxane D. , Stamos, Michael J. , Sunderland, Michael, Tan, Ker‐Kan , Tanis, Pieter J. , Tekkis, Paris, Teklay, Biniam, Tengku, Sabrina , Jiménez‐Toscano, Marta , Turina, Matthias , Ulrich, Alexis , Vailati, Bruna Borba , Harten, Meike van, Warrier, Satish K. , Wexner, Steve, Wilt, Hans De, Xynos, Evangelos , You, Nancy, Zakharenko, Alexander, Zeballos, Justino, Winter, D. C. , Wexner, Steven D. , Hoffmeister, Michael , Seppälä, Toni T , Spinelli, Antonino , Wexner, Steven D , Ris, Frederic , Collaborative, REACCT, Andric, Mihailo , Bala, Miklosh , Biondo, Sebastiano , Brown, Carl James , Buchanan, Daniel D. , Buchwald, Pamela , Dapri, Giovanni , Davies, Justin , Denost, Quentin , Dias, André Roncon , Dziki, Adam Janusz , Emile, Sameh Hany , Evans, Martyn D. , Fleming, Fergal J. , Foppa, Caterina , Fowler, G , Gong, Jianping, Greenwood, Emma, Hahnloser, Dieter , Hampel, Heather , Hill, Andrew Graham , Islam, Rumana, Jafari, Mehrenah D, Карачун, А. М. , Krivokapić, Zoran , Kryžauskas, Marius , Kusters, Miranda , Lee, Suk-Hwan , Lefèvre, Jérémie H. , Lieu, Christopher H. , Martin, Sean, Millán, Mónica , Morărașu, Ștefan , Möslein, Gabriela , Nahas, Sérgio Carlos , Okabayashi, Koji , Олькина, Александра Юрьевна , Park, Jason , Patel, Swati , Petrov, Alexei, Rega, Daniela , Roxburgh, Campbell S.D. , Smart, Neil James , Solis, Alejandro, Steele, Scott R. , Владимирович, Царьков Петр , Verhoef, Cornelis , Weinberg, Benjamin A. , Wells, Cameron I. , Wolthuis, Albert M.

Mayo Clinic

JAMA Surgery | June 30, 2021 | Volume: 156 | Issue: 9 | Pages: 865

10.1001/jamasurg.2021.2380 | PMID 34190968 Get It